D.A. Davidson & CO. Boosts Stock Position in IQVIA Holdings Inc. $IQV

D.A. Davidson & CO. increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 25.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,190 shares of the medical research company’s stock after acquiring an additional 5,514 shares during the quarter. D.A. Davidson & CO.’s holdings in IQVIA were worth $6,129,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. purchased a new stake in shares of IQVIA in the fourth quarter worth $25,000. Physician Wealth Advisors Inc. raised its position in shares of IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares during the period. Westside Investment Management Inc. lifted its stake in shares of IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares in the last quarter. Measured Wealth Private Client Group LLC bought a new position in IQVIA in the 3rd quarter worth $30,000. Finally, Atlantic Union Bankshares Corp purchased a new stake in IQVIA in the 3rd quarter worth $36,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on IQV shares. JPMorgan Chase & Co. lowered their price objective on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. Royal Bank Of Canada began coverage on IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price on the stock. Truist Financial dropped their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. Jefferies Financial Group cut their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 6th. Finally, Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a report on Friday, March 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $226.63.

IQVIA Stock Down 2.9%

Shares of NYSE IQV opened at $159.04 on Wednesday. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The company has a market cap of $26.99 billion, a P/E ratio of 20.23, a PEG ratio of 1.63 and a beta of 1.39. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The firm has a 50-day simple moving average of $169.86 and a two-hundred day simple moving average of $202.19.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The company had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. During the same quarter in the prior year, the company posted $3.12 EPS. IQVIA’s quarterly revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 11.5 earnings per share for the current year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.